27321568|t|Efficacy of Intravenous Chlorothiazide for Refractory Acute Decompensated Heart Failure Unresponsive to Adjunct Metolazone
27321568|a|To assess the efficacy of intravenous chlorothiazide in patients with acute decompensated heart failure (ADHF) who were determined to be loop diuretic resistant and refractory to metolazone. Retrospective cohort study with patients serving as their own controls. Large, academic, tertiary care hospital. Forty-five patients with ADHF who had an inadequate response to high-dose loop diuretics and then received at least one dose of oral metolazone 5 mg or greater (metolazone index dose) followed by at least one dose of intravenous chlorothiazide 500 mg (chlorothiazide index dose) if the response to metolazone was considered inadequate, according to the institutional protocol, between February 4, 2013, and February 28, 2015, were included. If multiple doses of metolazone were administered, the last dose given before the chlorothiazide index dose was considered the index dose; the metolazone index dose had to have been administered more than 2 hours before the chlorothiazide index dose. Data for a total of 90 diuretic doses (45 metolazone, 45 chlorothiazide) were included in the analysis. The median dose of loop diuretic in intravenous furosemide equivalents given over the 24- hour period before the metolazone index dose was 400 mg. The average length of stay was 34.7 days, and in-hospital mortality was 35.6% (16/45 patients). The primary end point of a net-negative urine output of 500 ml or greater during the 12 hours after the index dose occurred in 42.2% (19/45 patients) and 35.5% (16/45 patients) for the chlorothiazide and metolazone doses, respectively (p=0.581). The median 12- hour urine output following administration of metolazone was 810 ml (interquartile range [IQR] 866 ml) versus 1075 ml (IQR 940 ml) following administration of chlorothiazide (p=0.363). Compared with metolazone, the chlorothiazide doses did not result in an increase in urine output of at least 500 ml during the 12 hours following the dose relative to the 12 hours before the dose (31.1% vs 22.2%, p=0.754). No significant difference in achievement of net-negative urine output of 500 ml or greater during the 12 hours following the chlorothiazide or metolazone dose was noted (42.2% for chlorothiazide vs 35.5% for metolazone, p=0.581). The addition of intravenous chlorothiazide did not result in improved diuresis in patients with ADHF determined to be refractory to loop diuretic s and adjunctive oral metolazone.
27321568	0	8	Efficacy	T080	C1280519
27321568	12	23	Intravenous	T082	C0348016
27321568	24	38	Chlorothiazide	T109,T121	C0008273
27321568	43	53	Refractory	T169	C0205269
27321568	54	87	Acute Decompensated Heart Failure	T047	C1609524
27321568	88	100	Unresponsive	T169	C0205269
27321568	104	111	Adjunct	T169	C1719882
27321568	112	122	Metolazone	T109,T121	C0025854
27321568	137	145	efficacy	T080	C1280519
27321568	149	160	intravenous	T082	C0348016
27321568	161	175	chlorothiazide	T109,T121	C0008273
27321568	179	187	patients	T101	C0030705
27321568	193	226	acute decompensated heart failure	T047	C1609524
27321568	228	232	ADHF	T047	C1609524
27321568	260	273	loop diuretic	T121	C0354100
27321568	274	283	resistant	T169	C0332325
27321568	288	298	refractory	T169	C0205269
27321568	302	312	metolazone	T109,T121	C0025854
27321568	314	340	Retrospective cohort study	T062	C2985505
27321568	346	354	patients	T101	C0030705
27321568	376	384	controls	T096	C0009932
27321568	386	391	Large	T081	C0549177
27321568	393	401	academic	T092	C1510747
27321568	403	425	tertiary care hospital	T073,T093	C0337954
27321568	438	446	patients	T101	C0030705
27321568	452	456	ADHF	T047	C1609524
27321568	468	478	inadequate	T080	C0205412
27321568	479	487	response	T032	C0871261
27321568	491	500	high-dose	T081	C0444956
27321568	501	515	loop diuretics	T121	C0354100
27321568	547	551	dose	T081	C0178602
27321568	555	559	oral	T082	C0442027
27321568	560	570	metolazone	T109,T121	C0025854
27321568	579	586	greater	T081	C1704243
27321568	588	598	metolazone	T109,T121	C0025854
27321568	599	609	index dose	T081	C0178602
27321568	636	640	dose	T081	C0178602
27321568	644	655	intravenous	T082	C0348016
27321568	656	670	chlorothiazide	T109,T121	C0008273
27321568	679	693	chlorothiazide	T109,T121	C0008273
27321568	694	704	index dose	T081	C0178602
27321568	725	735	metolazone	T109,T121	C0025854
27321568	751	761	inadequate	T080	C0205412
27321568	780	802	institutional protocol	T170	C0442711
27321568	880	885	doses	T081	C0178602
27321568	889	899	metolazone	T109,T121	C0025854
27321568	905	917	administered	T058	C0806914
27321568	928	932	dose	T081	C0178602
27321568	950	964	chlorothiazide	T109,T121	C0008273
27321568	965	975	index dose	T081	C0178602
27321568	995	1005	index dose	T081	C0178602
27321568	1011	1021	metolazone	T109,T121	C0025854
27321568	1022	1032	index dose	T081	C0178602
27321568	1050	1062	administered	T058	C0806914
27321568	1075	1080	hours	T079	C0439227
27321568	1092	1106	chlorothiazide	T109,T121	C0008273
27321568	1107	1117	index dose	T081	C0178602
27321568	1119	1123	Data	T078	C1511726
27321568	1142	1150	diuretic	T121	C0354100
27321568	1151	1156	doses	T081	C0178602
27321568	1161	1171	metolazone	T109,T121	C0025854
27321568	1176	1190	chlorothiazide	T109,T121	C0008273
27321568	1213	1221	analysis	T062	C0936012
27321568	1234	1238	dose	T081	C0178602
27321568	1242	1255	loop diuretic	T121	C0354100
27321568	1259	1270	intravenous	T082	C0348016
27321568	1271	1281	furosemide	T109,T121	C0016860
27321568	1313	1317	hour	T079	C0439227
27321568	1318	1324	period	T079	C1948053
27321568	1336	1346	metolazone	T109,T121	C0025854
27321568	1347	1357	index dose	T081	C0178602
27321568	1392	1396	stay	T079	C3489408
27321568	1406	1410	days	T079	C0439228
27321568	1416	1437	in-hospital mortality	T080	C0085556
27321568	1455	1463	patients	T101	C0030705
27321568	1478	1487	end point	T080	C2349179
27321568	1493	1505	net-negative	T033	C0205160
27321568	1506	1518	urine output	T201	C0232856
27321568	1554	1559	hours	T079	C0439227
27321568	1570	1580	index dose	T081	C0178602
27321568	1606	1614	patients	T101	C0030705
27321568	1633	1641	patients	T101	C0030705
27321568	1651	1665	chlorothiazide	T109,T121	C0008273
27321568	1670	1680	metolazone	T109,T121	C0025854
27321568	1681	1686	doses	T081	C0178602
27321568	1727	1731	hour	T079	C0439227
27321568	1732	1744	urine output	T201	C0232856
27321568	1755	1769	administration	T081	C0001555
27321568	1773	1783	metolazone	T109,T121	C0025854
27321568	1796	1815	interquartile range	T081	C1711350
27321568	1817	1820	IQR	T081	C1711350
27321568	1846	1849	IQR	T081	C1711350
27321568	1868	1882	administration	T081	C0001555
27321568	1886	1900	chlorothiazide	T109,T121	C0008273
27321568	1912	1920	Compared	T052	C1707455
27321568	1926	1936	metolazone	T109,T121	C0025854
27321568	1942	1956	chlorothiazide	T109,T121	C0008273
27321568	1957	1962	doses	T081	C0178602
27321568	1984	1992	increase	T169	C0442805
27321568	1996	2008	urine output	T201	C0232856
27321568	2042	2047	hours	T079	C0439227
27321568	2062	2066	dose	T081	C0178602
27321568	2086	2091	hours	T079	C0439227
27321568	2103	2107	dose	T081	C0178602
27321568	2179	2191	net-negative	T033	C0205160
27321568	2192	2204	urine output	T201	C0232856
27321568	2240	2245	hours	T079	C0439227
27321568	2260	2274	chlorothiazide	T109,T121	C0008273
27321568	2278	2288	metolazone	T109,T121	C0025854
27321568	2289	2293	dose	T081	C0178602
27321568	2315	2329	chlorothiazide	T109,T121	C0008273
27321568	2343	2353	metolazone	T109,T121	C0025854
27321568	2381	2392	intravenous	T082	C0348016
27321568	2393	2407	chlorothiazide	T109,T121	C0008273
27321568	2426	2434	improved	T033	C0184511
27321568	2435	2443	diuresis	T042	C0012797
27321568	2447	2455	patients	T101	C0030705
27321568	2461	2465	ADHF	T047	C1609524
27321568	2483	2493	refractory	T169	C0205269
27321568	2497	2510	loop diuretic	T121	C0354100
27321568	2517	2527	adjunctive	T169	C1719882
27321568	2528	2532	oral	T082	C0442027
27321568	2533	2543	metolazone	T109,T121	C0025854